Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Newsletters
The Entrepreneurs Report – Q1 2026
Wilson Sonsini is pleased to present the Q1 2026 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the first quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Newsletters
Wilson Sonsini Global Cartel Law Quarterly Q4 2025/Q1 2026
The firm is pleased to distribute the Wilson Sonsini Global Cartel Law Quarterly Q4 2025/Q1 2026, which provides a summary of key cartel enforcement trends across the U.S., Europe, and beyond. A “cartel” under competition law is typically reserved for agreements between competitors to restrict competition, such as price-fixing, bid-rigging, and market allocations.
All Results
Client Highlights
6.18.26
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
Client Highlights
6.18.26
Wilson Sonsini Advises SandboxAQ on Agreement with the U.S. Department of Commerce for $500 Million CHIPS R&D Award
On June 17, 2026, SandboxAQ announced a definitive agreement with the U.S. Department of Commerce's CHIPS Research and Development Office for a $500 million award to address one of the most urgent challenges in American manufacturing: the foreign control of critical materials and chemistries that are essential to semiconductor manufacturing. Wilson Sonsini Goodrich & Rosati advised SandboxAQ on the transaction.
News Articles
6.18.26
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 500 Leading Global IP Lawyers Guide
On June 18, 2026, Lawdragon published the 2026 edition of its 500 Leading Global IP Lawyers guide, recognizing the leading attorneys that are protecting innovation, defending brand integrity, and leveraging the assets at the heart of their clients' businesses. Wilson Sonsini partners Wendy Devine, Jordan Jaffe, David Kramer, and James Yoon have been named to the 2026 guide.
Alerts
6.17.26
Delaware Court of Chancery Interprets New Section 144 and Applies Heightened Presumption of Director Independence
On June 15, 2026, the Delaware Court of Chancery issued an Opinion interpreting Section 144 of the Delaware General Corporation Law (the DGCL), the landmark statutory measure adopted last year to provide safe harbors for certain conflicted transactions and address director independence, among other reforms.1 The Opinion arose in a common context in Delaware stockholder litigation: claims over director and management compensation. In the decision, Vice Chancellor Lori W. Will applied, for the first time, the statute’s heightened presumption of independence for directors of public companies determined by the board to be independent under the relevant NYSE or Nasdaq listing standards to dismiss derivative claims on demand futility grounds.
Alerts
6.17.26
Key U.S. Import Developments, June 2026
With new and novel tariffs yielding to court decisions rendering those tariffs unlawful (only to be replaced with newer tariffs—and more litigation about the newer tariffs), and with the Section 122 temporary import surcharge of 10 percent nearing expiration in a matter of weeks, businesses have faced extraordinary uncertainty in navigating trade policy.
Alerts
6.17.26
UK Announces Social Media Ban and Broader Online Restrictions for Users Under 16
On June 15, 2026, the UK government announced plans to introduce a social media ban for users under 16 (under-16s), alongside restrictions on features deemed harmful to minors, such as livestreaming and messaging functions, for a wider range of online services, including those in the gaming sector. These measures, which may require platforms active in the UK market to significantly alter their operations, are expected to come into force in Spring 2027.
Client Highlights
6.17.26
Wilson Sonsini Advises Energy Dome on Collaboration Agreement with Salt River Project
On June 15, 2026, Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, announced an agreement to add a 19-megawatt, 10-hour carbon dioxide-based battery system to the grid. The project is part of Google and SRP’s innovative collaboration to accelerate deployment of non-lithium-ion long-duration energy storage technologies that support reliability, affordability, and sustainability. Wilson Sonsini Goodrich & Rosati advised Energy Dome on the transaction.
Client Highlights
6.17.26
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
6.16.26
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Alerts
6.15.26
Delaware Enacts Uniform Assignment for the Benefit of Creditors Law
On June 10, 2026, Delaware joined four other states and enacted a version of the Uniform Assignment for the Benefit of Creditors Act (the Act). The Act constitutes a significant change to Delaware’s prior statute, first enacted in 1875, and modernizes and streamlines Delaware’s assignment for the benefit of creditors process.1
Bylined Articles
6.15.26
Law360 Article: “7 Key Questions About SEC’s Faster Tender Offer Path”
Wilson Sonsini attorneys Rob Ishii, Doug Schnell, Remi Korenblit, Tamara Brightwell, and Michael Anthony authored a recent Law360 article titled "7 Key Questions About SEC’s Faster Tender Offer Path." The piece examines the recent order issued by the SEC to shorten the minimum offering period on certain equity tender offers. The authors walk through seven key questions covering eligibility requirements, timeline implications, private company applicability, and strategic considerations—noting that while the shortened period offers meaningful efficiency gains, parties must carefully weigh trade-offs, including reduced time for boards to consider topping proposals and potential sequencing issues with go-shop periods.